Pila Pharma ABFRA:5KC +2.87%49 PS Ratio is 26.88 as of Jul. 07, 2026, which is 62% below its 10-year median of 70.18. GuruFocus rates FRA:5KC with a GF Score™ of 49/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review. Among 929 Biotechnology companies, Pila Pharma AB ranks worse than 72.87% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pila Pharma AB's share price is €0.1075.
Pila Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Hence, Pila Pharma AB's PS Ratio for today is 26.88.
The historical rank and industry rank for Pila Pharma AB's PS Ratio or its related term are showing as below:
FRA:5KC'
s PS Ratio Range Over the Past 10 Years
Min: 10.35 Med: 70.18 Max: 568.51
Current: 31.67
During the past 8 years, Pila Pharma AB's highest PS Ratio was 568.51. The lowest was 10.35. And the median was 70.18.
FRA:5KC's PS Ratio is ranked worse than 72.87% of 929
companies
in the Biotechnology industry
Industry Median: 9.64
vs FRA:5KC: 31.67
Pila Pharma AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Pila Pharma AB was 10.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -30.20% per year.
During the past 8 years, Pila Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 72.20% per year. The lowest was -30.20% per year. And the median was -15.10% per year.
Back to Basics: PS Ratio
Pila Pharma AB (FRA:5KC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pila Pharma AB PS Ratio Related Terms
Pila Pharma AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Pila Pharma AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pila Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pila Pharma AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pila Pharma AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pila Pharma AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pila Pharma AB's Share Price of today is €0.1075.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pila Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pila Pharma AB (FRA:5KC) has a PS Ratio of 26.88 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pila Pharma AB and its competitors. This is 62% below median its historical median of 70.18. Over the past decade, Pila Pharma AB's PS Ratio has ranged from 10.35 to 568.51. According to the industry distribution chart, Pila Pharma AB ranks #677 out of 929 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Pila Pharma AB's PS Ratio too high?
Pila Pharma AB's current PS Ratio of 26.88 is 62% below median its 10-year median of 70.18. Over the past 10 years, this metric has ranged from a low of 10.35 to a high of 568.51. The Biotechnology industry median PS Ratio is 9.64. Pila Pharma AB's value of 26.88 is 178.8% above this industry median. Based on the distribution chart, Pila Pharma AB ranks #677 out of 929 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pila Pharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pila Pharma AB ranks #677 out of 929 companies for PS Ratio. This places Pila Pharma AB in the lower half of its industry. The industry median PS Ratio is 9.64. Pila Pharma AB's value of 26.88 is 178.8% above this benchmark. Historically, Pila Pharma AB's own PS Ratio has ranged from 10.35 to 568.51 over the past decade. While the company's 10-year median is 70.18 vs. the industry median of 9.64, Pila Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pila Pharma AB's current PS Ratio of 26.88 is 178.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pila Pharma AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pila Pharma AB's current PS Ratio is 26.88, which is 62% below median its own 10-year median of 70.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current PS Ratio of 26.88. The stock's GF Value™ is €0.15, compared to a current price of €0.11 — trading 28.3% below its estimated fair value. The current PS Ratio is 26.88, which is 62% below median its 10-year median of 70.18 and 178.8% above the Biotechnology industry median of 9.64. Pila Pharma AB's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current PS Ratio is 26.88 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?
Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued.
The current stock price of €0.11 is trading 28.3% below its estimated GF Value™ of €0.15.
Key valuation signals for FRA:5KC:
PS Ratio: 26.88 (62% below median its 10-year median of 70.18)
GF Value™: €0.15 vs. price of €0.11 (28.3% below fair value)
Industry Position: 178.8% above the Biotechnology median (#677 of 929)
No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
49GF Score
Get the complete analysis for FRA:5KC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5KC has been successfully added to your 
